Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
Stroke
|
January 4, 2011
Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke
Mohammad Al-Tamimi, Elizabeth E Gardiner, Jim Y Thom, et al.
British Journal of Haematology
|
February 26, 2013
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
David J Kuter, James B Bussel, Adrian Newland, et al.
Blood
|
September 13, 2007
Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa
Elizabeth E Gardiner, Denuja Karunakaran, Jane F Arthur, et al.
The New England Journal of Medicine
|
July 11, 2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
Agnes Y Y Lee, Mark N Levine, Ross I Baker, et al.
Frontiers in Immunology
|
November 11, 2021
Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
Bruce D Wines, Halina M Trist, Sandra Esparon, et al.
The New England Journal of Medicine
|
July 2, 2019
A Multicenter Trial of Vena Cava Filters in Severely Injured Patients
Kwok M Ho, Sudhakar Rao, Stephen Honeybul, et al.
Blood
|
July 12, 2024
The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1
Alain Chion, Ciara Byrne, Ferdows Atiq, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 30, 2021
ADAMTS13 regulation of VWF multimer distribution in severe COVID-19
Soracha E Ward, Helen Fogarty, Ellie Karampini, et al.
Research and Practice in Thrombosis and Haemostasis
|
February 23, 2023
Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19
Ellie Karampini, Helen Fogarty, Stephanie Elliott, et al.
Thrombosis and Haemostasis
|
December 23, 2016
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B
K John Pasi, Kathelijn Fischer, Margaret Ragni, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
Stroke
|
January 4, 2011
Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke
Mohammad Al-Tamimi, Elizabeth E Gardiner, Jim Y Thom, et al.
British Journal of Haematology
|
February 26, 2013
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
David J Kuter, James B Bussel, Adrian Newland, et al.
Blood
|
September 13, 2007
Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa
Elizabeth E Gardiner, Denuja Karunakaran, Jane F Arthur, et al.
The New England Journal of Medicine
|
July 11, 2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
Agnes Y Y Lee, Mark N Levine, Ross I Baker, et al.
Frontiers in Immunology
|
November 11, 2021
Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
Bruce D Wines, Halina M Trist, Sandra Esparon, et al.
The New England Journal of Medicine
|
July 2, 2019
A Multicenter Trial of Vena Cava Filters in Severely Injured Patients
Kwok M Ho, Sudhakar Rao, Stephen Honeybul, et al.
Blood
|
July 12, 2024
The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1
Alain Chion, Ciara Byrne, Ferdows Atiq, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 30, 2021
ADAMTS13 regulation of VWF multimer distribution in severe COVID-19
Soracha E Ward, Helen Fogarty, Ellie Karampini, et al.
Research and Practice in Thrombosis and Haemostasis
|
February 23, 2023
Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19
Ellie Karampini, Helen Fogarty, Stephanie Elliott, et al.
Thrombosis and Haemostasis
|
December 23, 2016
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B
K John Pasi, Kathelijn Fischer, Margaret Ragni, et al.
Page
of 6